AUTOLUS THERAPEUTICS PLC Stock Price, News & Analysis

Autolus Therapeutics (AUTL) reported a 100% complete remission rate in patients with indolent B Cell Non-Hodgkin lymphoma, alongside robust CAR T engraftment. No severe Cytokine Release Syndrome (CRS) or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) occurred. In adult Acute Lymphoblastic Leukemia (ALL), 85% achieved minimal residual disease-negative complete remission. The event-free survival rate at 12 months is 50.2%, indicating potential for obe-cel as a transformative therapy. A conference call on findings will be held on June 11.

Autolus Therapeutics (NASDAQ: AUTL) announced insights from a Nature Cancer publication on the durability of acute lymphoblastic leukemia (ALL) treatments using AUTO1. The findings reveal that long-term response in pediatric ALL patients correlates with an enrichment of Stem Cell Memory T cells (T_SCM). These T_SCM cells are believed to support sustained immune response. AUTO1's design encourages efficient targeting and minimized T cell exhaustion, enhancing its therapeutic potential. The investigational therapy is being evaluated in ongoing clinical trials.

Autolus Therapeutics (Nasdaq: AUTL) announced its Annual General Meeting (AGM) scheduled for June 18, 2021, at its headquarters in White City, London. Due to COVID-19 restrictions, in-person attendance is prohibited, and a minimum quorum of two shareholders is required. Shareholders are encouraged to submit proxy votes ahead of the meeting as voting during the AGM will not be possible. No webcast will be provided this year, and results will be announced via press release afterwards.

Autolus Therapeutics plc (Nasdaq: AUTL) announced a 100% complete remission rate in a cohort of patients with relapsed/refractory indolent B cell lymphomas (IBCL) treated with its investigational therapy, AUTO1. The early results were presented at the European Hematology Association Virtual Congress on June 9-17, 2021. Of the 10 patients treated, 9 were evaluable, and 8 remain in ongoing remission at a median of 3.1 months. Importantly, no high-grade cytokine release syndrome or neurotoxicity was observed, indicating a favorable safety profile for AUTO1.

Autolus Therapeutics (Nasdaq: AUTL) reported Q1 2021 results, showing a net loss of $33.3 million or $(0.53) per share. Cash reserves amounted to $239 million, up from $153.3 million at year-end 2020. The company is focusing on its AUTO1 program, with upcoming data expected in 2022 from pivotal studies. The firm also received PRIME designation for AUTO1 in the EU, and innovative licensing for AUTO4 in PTCL. Operational changes aim to save $15 million annually. A follow-on public offering generated $106.9 million in February 2021. Management expects cash runway to last into H1 2023.

Autolus Therapeutics plc (Nasdaq: AUTL) announced it will release its Q1 2021 financial results and operational highlights on May 6, 2021, before U.S. market open. Management will host a conference call at 8:30 am ET to discuss these results and provide a business update. Interested parties can access the webcast on Autolus' website or dial in via provided numbers. A replay of the call will be available post-event.

Autolus Therapeutics plc (Nasdaq: AUTL) has received the Innovative Licensing and Access Pathway (ILAP) designation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for AUTO4, a product in Phase 1 trials for TRBC1 positive Peripheral T Cell Lymphoma (PTCL). This designation follows the PRIME designation received for AUTO1, aimed at accelerating the review of therapies addressing unmet medical needs. The ILAP facilitates enhanced dialogue with regulators and access to development tools, potentially leading to faster patient access in the UK.

Autolus Therapeutics plc (Nasdaq: AUTL) appointed Dr. Martin Murphy as non-executive chairman of its Board of Directors, effective April 15, 2021. This change follows Dr. Christian Itin's long tenure as chairman and CEO since the company's inception in 2014. The separation of these roles aims to enhance leadership focus as the lead program, AUTO1, progresses through clinical trials and gears up for potential commercialization. Dr. Murphy brings over 25 years of life sciences experience, previously serving as a non-executive director since 2014.

Autolus Therapeutics plc (Nasdaq: AUTL) announced participation in several investor conferences throughout April 2021. Key events include the Wells Fargo Annual Biotech Corporate Access on April 6 and 8, and the 20th Annual Needham Virtual Healthcare Conference on April 14, where the CEO and CFO will engage in a Fireside Chat. Additionally, Autolus will partake in the Raymond James Oncology Summit on April 22 and Kempen & Co. European Life Sciences: Gene, Cell, and RNA Day on April 28. This participation highlights Autolus's commitment to advancing its next-generation T cell therapies for cancer treatment.